Novartis Says Psoriasis Drug Met End-Goal of Arthritis Studies

September 25, 2014 6:49 AM

6 0

Novartis AG (NOVN) said an experimental drug worked better than a placebo in two advanced clinical tests on psoriatic arthritis, improving the prospects for winning regulatory approval.

Novartis plans to file globally for approval to sell the drug, called secukinumab, next year, the Basel, Switzerland-based drugmaker said today in a statement.

Also read: FDA approves Newron's drug as add-on therapy for Parkinson's

Read more

To category page